LAMA 在哮喘-COPD 重叠患者中的获益：一项系统评价和荟萃分析。
Benefits of LAMA in patients with asthma-COPD overlap: A systematic review and meta-analysis.
机构信息
Radioimmunoassay Center, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China.
Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710061, China.
出版信息
Clin Immunol. 2022 Apr;237:108986. doi: 10.1016/j.clim.2022.108986. Epub 2022 Mar 25.
PURPOSE
A systematic review and meta-analysis to determine the efficacy of long-acting muscarinic antagonist (LAMA) in patients with asthma-COPD overlap (ACO) was conducted.
METHODS
A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of ACO with LAMA, compared with placebo or blank, were reviewed.
RESULTS
Six RCTs (enrolling 1151 participants) met the inclusion criteria. LAMA showed significant effects on forced expiratory volume in 1 s (FEV) (WMD 98.31 mL, 95% CI 94.32 to 102.30 mL), forced vital capacity (FVC) (WMD 128.00 mL, 95% CI 121.89 to 134.12 mL), peak expiratory flow (PEF) (WMD 20.60 L/min, 95% CI 19.90 to 21.29 L/min), and rescue medicine use (WMD -0.67 puffs/day, 95% CI -1.11 to -0.23 puffs/day).
CONCLUSIONS
The addition of LAMA significantly improved lung function and rescue medicine use in patients with asthma-COPD overlap.
目的
系统评价和荟萃分析旨在确定长效毒蕈碱受体拮抗剂（LAMA）在哮喘-慢性阻塞性肺疾病重叠（ACO）患者中的疗效。
方法
系统检索了 PubMed、Embase、Cochrane 图书馆和 clinicaltrials.gov，不限制语言。综述了 LAMA 治疗 ACO 与安慰剂或空白对照的随机对照试验（RCT）。
结果
符合纳入标准的 6 项 RCT（共纳入 1151 名参与者）。LAMA 在 1 秒用力呼气量（FEV）（WMD 98.31mL，95%CI 94.32 至 102.30mL）、用力肺活量（FVC）（WMD 128.00mL，95%CI 121.89 至 134.12mL）、呼气峰流速（PEF）（WMD 20.60L/min，95%CI 19.90 至 21.29L/min）和急救药物使用（WMD -0.67 吸/天，95%CI -1.11 至 -0.23 吸/天）方面均显示出显著效果。
结论
在哮喘-慢性阻塞性肺疾病重叠患者中，加入 LAMA 可显著改善肺功能和急救药物的使用。
Zotero 插件